Coeptis Aims to Bring AI Innovation in Biotechnology and
Technology
WEXFORD,
Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company specializing in innovative
cell therapy platforms for cancer, autoimmune, and infectious
diseases, proudly announces the completion of its acquisition of
the NexGenAI Affiliates Network platform alongside the official
launch of Coeptis Technologies. This new division is strategically
aimed at diversifying the company's growth potential.
The acquisition of the NexGenAI Affiliates Network
platform, which was developed by NexGenAI Solutions Group, Inc. and
its affiliates ("NexGenAI"), offers what Coeptis views as
groundbreaking AI-powered marketing software and advanced robotic
process automation (RPA) capabilities. This transformative
AI-powered tool is designed to empower marketers to process vast
amounts of data, optimize campaigns, enhance customer engagement,
and streamline operations—crucial elements in the highly regulated
sectors of biotech, pharmaceutical, and multi-level marketing (MLM)
industries.
Dave Mehalick, President and CEO of Coeptis Therapeutics,
stated, "We are excited to integrate the NexGenAI Affiliates
Network platform and its AI and RPA-driven tools into our
offerings. In industries like biotech, pharma, and MLM, where
competition is so high and regulatory challenges are complex,
having advanced tools to optimize marketing, streamline operations,
and drive measurable results is critical."
Anshuman Dash, Lead Advisory
behind the development of the NexGenAI Affiliates Network platform,
commented, "The integration of NexGenAI's innovative AI-powered
marketing solutions with Coeptis Therapeutics' forward-thinking
approach marks a transformative step forward. This acquisition
aligns nicely with Coeptis' mission to drive innovation in highly
regulated industries, revolutionize marketing strategies and
operational efficiencies and ultimately deliver greater value to
the partners and the industries served."
This acquisition reflects Coeptis' commitment to leveraging
advanced technologies to enhance its capabilities and drive
innovation within the biopharmaceutical sector. By incorporating
NexGenAI's AI-powered marketing solutions, Coeptis aims to provide
state-of-the-art tools to companies seeking to overcome marketing
challenges in competitive and highly regulated industries.
Dave Mehalick elaborated further on the NexGenAI Affiliates
Network platform acquisition, stating, "In highly competitive
industries such as biotech, pharma, and MLM, having advanced tools
to optimize marketing, streamline operations, and drive measurable
results is not just beneficial—it's essential for our success."
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics, Inc., Coeptis
Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP
Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio is highlighted by assets
licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms in collaboration with VyGen-Bio and
leading medical researchers at the Karolinska
Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned
subsidiary NexGenAI Solutions Group, Inc., has developed a
proprietary suite of advanced tools that power the NexGenAI
Affiliates Network platform. These tools, featuring AI-driven
marketing software and robotic process automation capabilities, are
designed to optimize campaigns, streamline operations, and provide
actionable, data-driven insights. NexGenAI's platform provides
cutting-edge AI-driven solutions that revolutionize business
operations across various sectors. By leveraging artificial
intelligence, NexGenAI empowers companies to automate processes,
optimize efficiency, and drive sustainable growth. For more
information on NexGenAI, visit nexgenai.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the inability to recognize the anticipated
benefits of the Deverra licensed assets, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(3) the risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-makes-bold-strides-in-innovation-with-the-acquisition-of-nexgenai-affiliates-network-platform-and-launch-of-coeptis-technologies-302339010.html
SOURCE Coeptis Therapeutics, Inc.